Loading…
← CockpitCompetitor Analysis › CTNM Contineum Therapeutics, Inc. Class AOpen in the cockpit ↗

Contineum Therapeutics, Inc. Class ACTNMCompetitor analysis, valuation and peers

United States · USD·Health Care›Biotechnology
Momentum weak 20
Mkt cap
$363M
US dollars, full cap
Free float
90%
of shares outstanding
$/day
$3.94M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
n/a
WACC 10.3%
Hurdle
n/a
no reverse DCF
Next earnings
113 days
11 Mar 2027
Close · USD$9.24
1D-3.2%
1W-14.2%
1M+9.2%
3M-42.3%
6M-31.0%
YTD-19.2%
1Y-17.1%
ATR %8.8%
Beta1.54
52w lowhigh48.0% off high

What Contineum Therapeutics does

Employees: 51

Contineum Therapeutics at a glance

Size Contineum Therapeutics (CTNM) is a United States Health Care company (Biotechnology) with a market value of $363M, the 2925th largest of 3,085 United States companies the cockpit tracks. Shares closed at $9.24 on 18 Nov 2026.

Performance Over six months the shares fell 31.0%, against -24.5% for the median peer and -2.2% for the United States market (cap-weighted) — 10th lowest of 20 in its peer set.

Short interest Short interest is 10.5% of the free float (30 Oct 2026).

Next results Next results expected around 11 Mar 2027 (exchange calendar; dates can move).

Relative performance

507510012521 May 202621 Aug 202618 Nov 2026Peer median 70CTNM 64
Six months, rebased to 100: Contineum Therapeutics against the median of its 20 peers (local-currency closes).

Contineum Therapeutics financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$0$0$0$50.0M$0
Revenue growth——-100%——
Gross profit-$383,000-$323,000-$258,000$49.8M-$329,000
EBITDA-$72.0M-$67.7M-$50.6M$16.3M-$22.4M
Net income-$63.5M-$60.0M-$42.3M$22.7M-$24.3M
Free cash flow-$52.0M-$55.5M-$33.4M$18.9M-$20.2M
Capital expenditure$360,000$231,000$514,000$414,000$118,000
Total debt$6.27M$8.25M$6.26M$193M$138M

Quarterly statements and history in the cockpit →

Contineum Therapeutics competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-40%-20%0%+20%-25%0%+25%476060CRMD300381086900PRTCALECLYEL300966358570PNVLRMR688687300683388068809821051167CTNM6-month return →1-month return →
Up and to the right = strong over both horizons. Contineum Therapeutics is the large dot.

Contineum Therapeutics competitors and peer comparison

How Contineum Therapeutics compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Contineum Therapeutics against its 20 peers (data as of 18 Nov 2026)
MeasureCTNMPeer medianRank in peer set
1-month return+9.2%-5.7%4th highest of 20
6-month return-31.0%-24.5%10th lowest of 20
Distance from 52-week high-48.0%-49.8%10th highest of 20

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Contineum Therapeutics CTNMUnited States$363M-31%n/an/an/an/an/a
Onconic Therapeutics 476060.KSSouth Korea$368M-49%+179%21%5.2×0.6%+725.2%
CorMedix CRMDUnited States$358M-43%+92%39%0.4×n/an/a
Guangdong Vtr Bio-Tech 300381.SZChina$370M-31%0%-4%2.6×n/an/a
Medy-Tox 086900.KSSouth Korea$350M-36%+3%10%2.2×4.7%+11.9%
Aspen Neuroscience ASPEUnited States$349Mn/an/an/an/an/an/a
PureTech Health PRTC.LUnited Kingdom$378M-15%-4%-1,617%27.4×n/an/a
Alector ALECUnited States$383M+21%+151%25%1.5×n/an/a
Lyell Immunopharma LYELUnited States$341M-19%-63%-1,388,360%13,911.5×n/an/a
Hubei Goto Biopharm 300966.SZChina$386M-16%+6%-10%6.0×n/an/a
GI Innovation 358570.KSSouth Korea$339M-47%+1,527%-918%78.5×n/an/a
Polynovo PNV.AXAustralia$388M-34%+13%5%3.9×51.9%+37.6%
Larimar Therapeutics LRMRUnited States$337M-9%n/an/an/an/an/a
Beijing Kawin Technology Share-Holding 688687.SSChina$391M-20%+6%-2%1.7×36.6%+8.9%
Wuhan Hiteck Biological Pharma 300683.SZChina$395M-41%-30%-27%5.2×n/an/a
Beijing Luzhu Biotechnology 2480.HKHong Kong$396M-33%n/an/an/an/an/a
Medtide 3880.HKHong Kong$331M-17%+14%36%2.4×n/an/a
Shanghai Shen Lian Biomedical 688098.SSChina$402M-22%-17%-16%10.9×n/an/a
Laekna 2105.HKHong Kong$326M-53%n/a-57%4.7×n/an/a
Jacobio Pharmaceuticals 1167.HKHong Kong$404M-24%+286%68%1.9×-18.8%-36.1%
C4 Therapeutics CCCCUnited States$325M-25%+7%-316%5.4×n/an/a

Questions

Which companies are Contineum Therapeutics's closest peers?
The cockpit's peer set: Onconic Therapeutics (476060.KS), CorMedix (CRMD), Guangdong Vtr Bio-Tech (300381.SZ), Medy-Tox (086900.KS), Aspen Neuroscience (ASPE), PureTech Health (PRTC.L), Alector (ALEC), Lyell Immunopharma (LYEL).
How has Contineum Therapeutics stock performed?
Over six months to 18 Nov 2026 the shares returned -31.0% against -24.5% for the median peer; over one year -17.1%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.